Taken together, these data demonstrate the critical role of EGFR kinase activity in normal tissue homeostasis and the response to injury, and the limitations of the use of TKIs and EGFR-targeting antibodies in patients with cancer due to their detrimental effect on normal tissue physiology. This evidence concerns the gene EGFR and cancer.